Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Golden Cariboo (CSE:GCC) (OTC:GCCFF) Expands Gold Footprint in BC (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Allarity Therapeutics Inc
ALLR
Healthcare
Biotechnology
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes...
Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:ALLR)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
Next
(1034)
•••
Iseneschal
X
Comment by
Iseneschal
on Sep 05, 2025 3:32pm
RE:RE:ALLR....less than 1 hr before the close on a Fryday
And just to quantify....I don't have a position...I sold it too early about a week ago But I still like this
(1034)
•••
Iseneschal
X
Comment by
Iseneschal
on Sep 05, 2025 3:30pm
RE:ALLR....less than 1 hr before the close on a Fryday
1/2 hr to go....N.H.O.D $1.95....LFG ; )
(1034)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 05, 2025 3:10pm
ALLR....less than 1 hr before the close on a Fryday
I'd say this is going to rip up...right f'king now ....$1.92
(1034)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 29, 2025 10:35am
ALLR....nice opening Price Action ....N.H.O.D of $1.70
Then a retracement followed by a grinding up-trend to over $1.60 On watch for gap up....JMHO
(1034)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 27, 2025 11:44am
ALLR....Sold all
No position
(1034)
•••
Iseneschal
X
Comment by
Iseneschal
on Aug 27, 2025 10:19am
RE:ALLR......On watch at $1.50
Now at $1.62
(1034)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 27, 2025 10:01am
ALLR......On watch at $1.50
Cheers
(187)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Aug 26, 2025 8:46am
Buy buddy buy because it's taking off this morning.
Otherwise FOMO
(1)
•••
stock2watch1
X
Post by
stock2watch1
on Jul 17, 2025 1:27pm
$ALLR interesting here..
https://allarity.com/
(1)
•••
stock2watch1
X
Post by
stock2watch1
on Jul 15, 2025 3:10pm
ALLR = RALLY SOON
...................
(1034)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 11, 2024 6:21am
ALLR.....30 : 1 RS effective today
On watch and Halted pending RS Last at $0.1135
(1034)
•••
Iseneschal
X
Post by
Iseneschal
on Jul 26, 2024 9:03am
ALLR...Meeting Postponed
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting 2024-07-26 06:00 ET - News Release Boston (July 26, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”)
...more
(1034)
•••
Iseneschal
X
Post by
Iseneschal
on Jul 24, 2024 5:31am
ALLR.....more tricks this a.m....Volume ?
https://www.sec.gov/Archives/edgar/data/1860657/000121390024063581/ea020982201ex99-1_allarity.htm
(1034)
•••
Iseneschal
X
Post by
Iseneschal
on May 06, 2024 11:46am
ALLR.....More lies this a.m
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1 2024-05-06 05:00 ET - News Release - Stockholders’ equity
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 12, 2023 6:00am
New Press Release - Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
Boston (December 12, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced a transition...
read article.
Prev
1
2
3
4
5
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
New Gold Opportunities in the Cariboo Region (CSE:GCC) (OTC:GCCFF)
Podcasts